Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genzyme, a Sanofi Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult living donor renal transplant recipient
Age greater than or equal to 18
If female and of childbearing potential: a) must not be lactating; b) must have a negative serum B-human chorionic gonadotropin (HCG) test within 24 hours prior to Study Day 0 (Day of Transplant) and; c) must agree to practice an acceptable and reliable form of contraception during the study; and
Signed informed consent
You may not be if
Human Leukocyte Antibody (HLA) identical matched living donor transplant recipient
\> 2 previous transplants
Current panel reactive antibody (PRA) \> 20%
History of a positive cross-match with the donor
Active donor or recipient serology positive for human immunodeficiency virus (HIV), Hepatitis B virus (HBV) or Hepatitis C virus (HCV)
Loss of first kidney transplant in \< 1 year
History of noncompliance in clinical trial(s)
History of chronic CS or immunosuppressive use except for inhaled CS to treat asthma
Use of any investigational products during the 90 days prior to screening
Requirement for multiple organ transplant
Patient without a functioning urinary bladder prior to transplant (e.g. patients with self catheterization will be excluded)
Known contraindication to administration of rabbit antithymocyte globulin
Currently abusing drugs or alcohol
In the opinion of the investigator, at high risk for poor compliance
In the opinion of the investigator, has a significant medical or psychosocial problem or unstable disease state that warrants exclusion from the study. Examples of significant problems include, but are not limited to morbid obesity and severe cardiac disease.
Clareo Health | A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection
